Lung Cancer

A phase I/II study will explore the delta-like protein 3-targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T) with the PD-1 inhibitor nivolumab (Opdivo) alone or in combination with the CTLA-4 inhibitor ipilimumab (Yervoy) for patients with relapsed extensive-stage small cell lung cancer.

The Committee for Medicinal Products for Human Use has adopted a positive option for crizotinib (Xalkori) as a treatment for adults with ROS1-positive advanced non–small cell lung cancer, suggesting an approval may be imminent.

Nathan Pennell, MD, PhD, discusses 3 available—and competing—agents in EGFR-mutant non–small cell lung cancer, as well as ongoing clinical trials at Cleveland Clinic exploring other regimens for this patient population.

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Mark W. Kris, MD, discusses immunotherapy, frontline therapies for nonsquamous non–small cell lung cancer, and advancements in squamous cell carcinoma.

Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.